Anticoagulant Associated Bleeding: Specific Populations and Reversal - report from ISTH 2026

Dr. Kerstin de Wit highlights critical updates on anticoagulant-associated bleeding risks, management, and reversal strategies presented at the ISTH 2026 Congress, featuring the following key studies:- Perioperative Anticoagulation Management and Outcomes in Thrombotic Antiphospholipid Syndrome: A Single-Center Cohort Study – Miguel Paquette (Ottawa, Canada)- The Incidence and Outcomes of LMWH-Related ISTH defined Major Bleeding: A National Observational Cohort Study – Gwendoline Fuller (London, UK)- Validation of a Treatment Decision Pathway for Andexanet Alfa (VALIDA) – Jan Beyer-Westendorf (Dresden, Germany)- Reversal efficacy of novel single domain antibodies against rivaroxaban, edoxaban or apixaban in vitro and ex vivo: studying platelet-dependent clot formation under flow – Xiang Gui (Maastricht, The Netherlands)Video: https://medicaldigest.org/scientific-contents/interview:anticoagulant-associated-bleeding-specific-populations-and-reversal